4//SEC Filing
BLOCH KATHLEEN P. 4
Accession 0001104659-22-090247
CIK 0001175151other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 6:47 PM ET
Size
12.9 KB
Accession
0001104659-22-090247
Insider Transaction Report
Form 4
BLOCH KATHLEEN P.
Chief Financial Officer
Transactions
- Award
Common Stock
2022-08-10+55,500→ 405,161 total - Award
Stock Option (right to buy)
2022-08-10+75,000→ 75,000 totalExercise: $1.95Exp: 2032-08-10→ Common Stock (75,000 underlying) - Award
Stock Option (right to buy)
2022-08-10+215,000→ 215,000 totalExercise: $1.95Exp: 2032-08-10→ Common Stock (215,000 underlying)
Holdings
- 33,700(indirect: See Note)
Common Stock
Footnotes (7)
- [F1]These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.
- [F2]Includes: (i) the following RSUs that will be settled into Common Stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;
- [F3](continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 16,484 RSUs granted on April 12, 2021 and unvested as of the date hereof and (b) 55,500 RSUs granted on August 10, 2022 reported on this Form 4 and unvested as of the date hereof; and
- [F4](continued from footnote 3) (iii) 151,677 shares of Common Stock owned by the Reporting Person.
- [F5]Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account, (ii) 15,000 shares held by the Reporting Person's husband in an IRA account and (iii) 8,700 shares held by the Reporting Person's husband in a ROTH IRA account. The Reporting Person may be deemed the beneficial owner of such shares.
- [F6]These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
- [F7]These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 45,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 45,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 50,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 75,000 options will vest if the Company achieves U.S. GAAP breakeven.
Documents
Issuer
Cytosorbents Corp
CIK 0001175151
Entity typeother
Related Parties
1- filerCIK 0001409212
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 6:47 PM ET
- Size
- 12.9 KB